Literature DB >> 8801172

Lung tumors in mice expressing an antisense RARbeta2 transgene.

J Bérard1, F Laboune, M Mukuna, S Massé, R Kothary, W E Bradley.   

Abstract

Retinoic acid has been shown to be an anticancer agent, and a growing literature suggests that it is the nuclear retinoic acid receptor beta2 (RARbeta2) that is primarily responsible for mediating this effect, at least in some systems. To determine whether partial inactivation of RARbeta2 would predispose to lung cancer in mice, we generated three transgenic lines expressing antisense sequences. When killed at 13-3/4-18 months of age, 21/36 animals had a total of 43 pulmonary tumors superficially visible upon necropsy, whereas among 23 nontransgenic mice, only 1 had a single visible lung tumor. A twofold higher incidence of lung tumors was seen in homozygous vs. hemizygous antisense mice. The endogenous RARbeta2 message level was reduced in transgenic lung tissue and further reduced in the tumors. RARbeta4, a truncated isoform derived from the same transcript as RARbeta2, does not carry the sequence identified by the antisense construct and its message was not as strongly affected. Immunofluorescence studies showed that RARbeta was virtually undetectable in the tumors, but present in normal tissue. We conclude that RARbeta2, but probably not RARbeta4, plays an important role in suppression of murine lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8801172     DOI: 10.1096/fasebj.10.9.8801172

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

1.  Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells.

Authors:  B Lin; G Q Chen; D Xiao; S K Kolluri; X Cao; H Su; X K Zhang
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 2.  Cytokine-induced tumor suppressors: a GRIM story.

Authors:  Dhan V Kalvakolanu; Shreeram C Nallar; Sudhakar Kalakonda
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

3.  Epigenetic regulation of retinoic acid receptor β2 gene in the initiation of breast cancer.

Authors:  Jingyan Sun; Xu Xu; Juntian Liu; Hong Liu; Li Fu; Lin Gu
Journal:  Med Oncol       Date:  2011-12       Impact factor: 3.064

Review 4.  Tumor-suppressive activity of retinoic acid receptor-beta in cancer.

Authors:  Xiao-Chun Xu
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

5.  Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis.

Authors:  H Qiu; W Zhang; A K El-Naggar; S M Lippman; P Lin; R Lotan; X C Xu
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

6.  Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer.

Authors:  Q Yang; I Mori; L Shan; M Nakamura; Y Nakamura; H Utsunomiya; G Yoshimura; T Suzuma; T Tamaki; T Umemura; T Sakurai; K Kakudo
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 7.  Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer.

Authors:  M Widschwendter; J Berger; H M Müller; A G Zeimet; C Marth
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

Review 8.  Aberrant DNA methylation in malignant melanoma.

Authors:  Carolina Schinke; Yongkai Mo; Yiting Yu; Kathy Amiri; Jeff Sosman; John Greally; Amit Verma
Journal:  Melanoma Res       Date:  2010-08       Impact factor: 3.599

9.  Integration of growth factor, extracellular matrix, and retinoid signals during bronchial epithelial cell differentiation.

Authors:  N Moghal; B G Neel
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

10.  Retinoid signaling regulates breast cancer stem cell differentiation.

Authors:  Christophe Ginestier; Julien Wicinski; Nathalie Cervera; Florence Monville; Pascal Finetti; François Bertucci; Max S Wicha; Daniel Birnbaum; Emmanuelle Charafe-Jauffret
Journal:  Cell Cycle       Date:  2009-10-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.